East Carolina University Issued U.S. Patents
Therapeutics
U.S. Patent No. 6,825,174
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
Inventor(s): Jonathan W. Nyce
Issued: November 30, 2004
Abstract: A pharmaceutical composition effective for preventing and alleviating bronchoconstriction, lung allergy(ies) and inflammation comprises a surfactant and an oligonucleotide anti-sense to an adenosine receptor gene, flanking regions or regions bridging the intro/exon borders, analogues which bind thymidine but have low adenosine content or exhibit lower or no adenosine receptor agonist activity, or antisense to the corresponding mRNA, combinations, sales or mixtures thereof, and a carrier, and optionally other therapeutic agents and formulation products. The composition is formulated for administration by a multiplicity of routes, and finds applications in the prevention and treatment of asthma, kidney damage or failure, ARDS, pulmonary vasoconstriction, inflammation, allergies, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), and cancer, to counter the renal damage and failure associated with ischemic conditions and the administration of certain drugs and radio active diagnostic and therapeutic agents, as well as a joint therapy with the administration of adenosine and adenosine-like agents in the treatment of arrhythmias such as SVT and in cardiovascular function tests (stress tests). The present agent(s) is (are) also suitable for administration before, during and after other treatments, including radiation, chemotherapy, antibody therapy, phototherapy and cancer, and other types of surgery.
U.S. Patent No. 6,670,349
Composition & Method for altering levels of or sensitivity to adenosine with a dehydroepiandrosterone &/or a ubiquinone
Inventor(s): Jonathan W. Nyce
Issued: December 30, 2003
Abstract: A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion. A method of treating asthma in a subject in need of such treatment is also disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effective to treat asthma.
U.S. Patent No. 6,432,924
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
Inventor(s): Jonathan W. Nyce
Issued: August 13, 2002
Abstract: A composition, device, kit and method for countering or diagnosing cytidine deaminase or deoxycytidine deaminase over-expression or a disorder associated with it, or an increase in number or toxicity of pro-inflammatory cells that over-express cytidine deaminase or deoxycytidine deaminase or a disorder associated with it, utilizing an agent of the formula C.sub.7 N.sub.3 H.sub.8 O.sub.2 R.sup.1 R.sup.2 XX.sup.1, wherein X and X.sup.1 are each independently C or N, R.sup.1 is lower alkyl, alkenyl and alkynyl, halogen or haloalkyl, and R.sup.2 is H, --N.sub.3 --OH, amino or halogen; or pharmaceutically acceptable salts thereof.
U.S. Patent No. 6,426,330
Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it
Inventor(s): Jonathan W. Nyce, Sherry Ann Leonard
Issued: July 30, 2002
Abstract: Satiety inducing composition comprises Neuropeptide Y analogues which are effective for inducing satiety and for treating diseases and conditions associated with a lacking of, or having lowered, satiety.
U.S. Patent No. 6,136,791
Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression
Inventor(s): Jonathan W. Nyce
Issued: October 24, 2000
Abstract: An agent of the chemical formula C.sub.7 N.sub.3 H.sub.8 O.sub.2 R.sup.1 R.sup.2 XX.sup.1, wherein X and X.sup.1 are each independently C or N but not simultaneously, R.sup.1 is lower alkyl, alkenyl or alkynyl, halogen or haloalkyl, and R.sup.2 is H, --N.sub.3 --OH, amino or halogen; or pharmaceutically acceptable salts thereof. A method of treating a disorder associated with the overexpression of cytidine deaminase or deoxycytidine deaminase comprises administering to a subject in need of the treatment a compound of the chemical formula ##STR1## wherein X and X.sub.1 are each independently C or N; R.sup.1 is lower alkyl, lower alkenyl, lower alkynyl, halogen, or haloalkyl; and R.sup.2 H, --N.sub.3, --OH, amino, or halogen; or a pharmaceutically acceptable salt thereof in an amount effective to treat the disorder. Pharmaceutical formulations useful in the method of the present invention are also disclosed.
U.S. Patent No. 6,087,351
Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone
Inventor(s): Jonathan W. Nyce
Issued: July 11, 2000
Abstract: A method and composition for reducing adenosine levels comprises administering a dehydroepiandrosterone, and optionally a ubiquinone.
U.S. Patent No. 6,075,009
Neuropeptide Y analogues, compositions and methods of lowering blood pressure
Inventor(s): Jonathan Nyce; Sherry Ann Leonard
Issued: June 13, 2000
Abstract: Neuropeptide Y analogues, and their compositions are effective for lower blood pressure.
U.S Patent No. 6,040,296
Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
Inventor(s): Jonathan W. Nyce
Issued: March 21, 2000
Abstract: A DNA comprises an oligonucleotide antisense to mRNA encoding an adenosine A.sub.1 or A.sub.3 receptor. The oligo is provided as a composition, various formulations, a capsule, and cartridge and in the form of a kit. The oligonucleotide of the invention is effective for reducing bronchoconstriction and/or allergy, and may be administered to a subject to treat respiratory ailments such as asthma and other conditions associated with the expression of adenosine receptors.
U.S. Patent No. 6,025,339
Composition, kit and method for treatment of disorders associated with
bronchoconstriction and lung inflammation
Inventor(s): Jonathan W. Nyce
Issued: February 15, 2000
Abstract: A method of reducing bronchoconstriction in a subject in need of such
treatment is disclosed. The method comprises administering to the subject an Antisense
oligonucleotide molecule directed against the A.sub.1 or A.sub.3 adenosine receptor in an
amount effective to reduce bronchoconstriction. The method is useful for treating patients
afflicted with asthma. Pharmaceutical formulations are also disclosed.
U.S. Patent No. 5,994,315
Low adenosine agent, composition, kit and method for treatment of airway disease
Inventor(s): Jonathan Nyce; James W. Metzger
Issued: November 30, 1999
Abstract: An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such treatment comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the airway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed.
U.S. Patent No. 5,993,804
Pharmaceutically acceptable fixed-dried human blood platelets
Inventor(s): Marjorie S. Read; Robert L. Reddick; Arthur P. Bode
Issued: November 30, 1999
Abstract: Fixed-dried human blood platelets and processes for preparing the same are disclosed. The platelets, upon reconstitution: adhere to thrombogenic surfaces; do not adhere to non-thrombogenic surfaces; undergo shape change (spreading) upon adhering to a thrombogenic surface; adhere to one another to form a hemostatic plug upon adhering to a thrombogenic surface; and release their granular contents. Pharmaceutical formulations containing the same are also disclosed. The platelets are preferably fixed by means of a fixative such as formaldehyde, paraformaldehyde, or glutaraldehyde, or fixed by means of a permanganate fixate. The platelets are preferably dried by lyophilization.
U.S. Patent No. 5,922,674
Method of treatment using chemotherapy and erythropoietin
Inventor(s): Athanasius A. Anagnostou; George Sigounas
Issued: July 13, 1999
Abstract: The use of human erythropoietin (EPO) to prevent or treat endothelial injury due to chemotherapy, radiation therapy, mechanical trauma, or to a disease state which damages the endothelium (such as inflammation, heart disease or cancer) is described. The use of EPO in conjunction with the administration of chemotherapeutic agents is described.
U.S. Patent No. 5,902,608
Surgical aids containing pharmaceutically acceptable fixed-dried human blood platelets
Inventor(s): Marjorie S. Read; Robert L. Reddick; Arthur P. Bode
Issued: May 11, 1999
Abstract: Fixed-dried human blood platelets and processes for preparing them are disclosed. The platelets, upon reconstitution: adhere to thrombogenic surfaces; do not adhere to non-thrombogenic surfaces; undergo shape change (spreading) upon adhering to a thrombogenic surface; adhere to one another to form a hemostatic plug upon adhering to a thrombogenic surface; and release their granular contents. Surgical aids containing such platelets are also disclosed. The platelets are preferably fixed by a fixative such as formaldehyde, paraformaldehyde, or glutaraldehyde, or fixed by a permanganate fixate. The platelets are preferably dried by lyophilization.
U.S. Patent No. 5,891,393
Method for the microbial decontamination of blood platelets
Inventor(s): Marjorie S. Read; Arthur P. Bode; Louis J. Summaria
Issued: April 6, 1999
Abstract: A method for inactivating microbiological contaminants in a human blood platelet preparation is disclosed. The method comprises, first, providing blood platelets, particularly human blood platelets, suspected of being contaminated with microorganisms. The platelets are then contacted to a fixative for a time sufficient to fix the platelets. After fixing, the platelets are preferably washed and dried to produce fixed-dried platelets. The step of contacting the platelets to a fixative is carried out for a time sufficient to kill some or all the of the contaminating microorganisms.
U.S. Patent No. 5,665,706
Nerve growth induction, stimulation and maintenance and enzyme potentiation
Inventor(s): John Paul Da Vanzo; Joseph West Paul, Jr.
Issued: September 9, 1997
Abstract: A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine hydroxylase by 2-amino-1,1,3-tricyano-1-propene are disclosed.
U.S. Patent No. 5,660,835
Method of treating adenosine depletion
Inventor(s): Jonathan W. Nyce
Issued: August 26, 1997
Abstract: A method of treating adenosine depletion in a subject in need of such treatment is disclosed. The method comprises administering to the subject folinic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat adenosine depletion. A method of treating asthma in a subject in need of such treatment is also disclosed. The method comprises administering to the subject dehydroepiandrosterone, analogs thereof, or pharmaceutically acceptable salts thereof in an amount effective to treat asthma.
U.S. Patent No. 5,554,590
Method of treating asthma
Inventor(s): Robert H. Fisher; W. James Metzger; Ruth A. Henriksen
Issued: September 10, 1996
Abstract: A method of treating asthma in a subject in need of such treatment comprises contacting Asthma Reversal Factor to the respiratory epithelium of the subject. The active agent is preferably contacted to the subject's respiratory epithelium by causing the subject to inhale respirable particles comprised of the active agent.
U.S. Patent No. 5,527,789
Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
Inventor(s): Johathan W. Nyce
Issued: June 18, 1996
Abstract: A method of combatting cancer in a subject comprising administering to said subject dehydroepiandrosterone (DHEA) or an analog thereof in an amount effective to combat cancer is disclosed in which heart failure induced by the DHEA or analog thereof is combatted by administering to the subject a ubiquinone, in an amount effective to combat heart failure induced by the DHEA or analog thereof. A prefered DHEA analog for carrying out the invention is 16 alpha-fluoroepiandrosterone, and a preferred ubiquinone for carrying out the invention is Coenzyme Q.sub.10.
U.S. Patent No. 5,475,019
Method of treating anxiety-related disorders with 2-aminocycloaliphatic amide compounds
Inventor(s): Thomas H. Privette; David M. Terrian
Issued: December 12, 1995
Abstract: A method for combatting anxiety in a subject in need of such treatment is provided. The method comprises administering to the subject a 2-aminocycloaliphatic amide kappa opioid agonist in an effective anxiety-combatting amount.
U.S. Patent No. 5,290,550
Method of treating asthma using IL-8
Inventor(s): Robert H. Fisher; James Metzger
Issued: March 1, 1994
Abstract: A method of treating asthma in a subject in need of such treatment comprises contacting Interleukin-8 or an active fragment thereof to the respiratory epithelium of the subject. The active agent is preferably human endothelial IL-8, and is preferably contacted to the subject's respiratory epithelium by causing the subject to inhale respirable particles comprised of the active agent.
U.S. Patent No. 5,194,426
Method for nerve growth induction
Inventor(s): John P. Da Vanzo; Paul, Jr.; Joseph W. Paul Jr.
Issued: March 16, 1993
Abstract: A composition comprising nerve growth factor and 2-amino-1,1,3-tricyano-1-propene useful for the induction, stimulation, and maintenance of nerve growth, and methods of potentiating choline O-acetyltransferase and tyrosine hydroxylase by 2-amino-1,1,3-tricyano-1-propene are disclosed.
U.S. Patent No. 4,994,367
Extended shelf life platelet preparations and process for preparing the same
Inventor(s): Arthur P. Bode; William A. L. Heaton; Stein Holme; David T. Miller
Issued: February 19, 1991
Abstract: A first aspect of the present invention is a blood platelet preparation comprising blood platelets, an adenylate cyclase stimulator, a phosphodiesterase inhibitor, a thrombin inhibitor, and a plasmin inhibitor. A second aspect of the present invention is a plasma-free platelet storage medium containing dextrose, sodium citrate, sodium bicarbonate, and a platelet activation inhibitor, with a preferred platelet activation inhibitor comprising an adenylate cyclase stimulator in combination with a phosphodiesterase inhibitor. A third aspect of the present invention is a process for producing a plasma-free platelet preparation comprising producing platelet-rich plasma (PRP) from whole blood, adding a platelet activation inhibitor thereto, centrifuging the PRP to deposit the platelets on the bottom of the centrifuge container, removing the platelet-free plasma supernatant therefrom and adding a plasma-free liquid platelet storage medium thereto. A preferred platelet activation inhibitor for the process comprises an adenylate cyclase stimulator in combination with a phosphodiesterase inhibitor. A preferred adenylate cyclase stimulator is Prostaglandin El, a preferred phosphodiesterase inhibitor is Theophylline, a preferred plasmin inhibitor is Aprotinin, and a preferred thrombin inhibitor is N-(2-naphthylsulfonylglycyl)-D,L-amidinophenylalaninpiperidide.
U.S. Patent No. 4,935,000
Extracellular matrix induction method to produce pancreatic islet tissue
Inventor(s): Ronald W. Dudek
Issued: June 19, 1990
Abstract: A method and composition of regenerating tissue. More specifically, a method for regenerating pancreatic islet tissue having the histological and insulin-containing properties of islets typically found in neonatal or adult animals is described. The regenerated islet tissue is produced by fetal mesenchyme acting upon an epithelium such that an inductive message causes the epithelium to differentiate into islet tissue.
U.S. Patent No. 7,358,039
Fixed-dried red blood cells
Inventor(s): Thomas Fischer, Marjorie Read, Arthur Bode, Timothy Nichols
Issued: April 15, 2008
Abstract: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.
U.S. Patent No. 7,351,805
Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
Inventor(s): Anne Kellogg, Diane Semer
Issued: April 1, 2008
Abstract: The present application describes a monoclonal antibody selected from the group consisting of monoclonal antibody DS6, monoclonal antibodies that specifically bind to the antigen or epitope bound by monoclonal antibody DS6, and fragments of the foregoing that specifically bind to the antigen or epitope bound by monoclonal antibody DS6. Methods of use of such antibodies and the isolated antigen bound by such antibodies are also described.
U.S. Patent No. 7,034,007
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
Inventor(s): Jonathan Nyce, James Metzger
Issued: April 25, 2006
Abstract: An in vivo method of selectively delivering a nucleic acid to a target gene or mRNA, comprises the topical administration, e.g. to the respiratory system, of a subject of a therapeutic amount of an oligonucleotide (oligo) that is anti-sense to a mRNA complementary to the gene in an amount effective to reach the target polynucleotide and reducing or inhibiting expression. The composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, lung allergy(ies) and/or inflammation and depletion lung surfactant or surfactant hypoproduction, such as pulmonary vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction. The treatment of this invention may be administered directly into the respiratory system of a subject so that the agent has direct access to the lungs, in an amount effective to reduce or inhibit the symptoms of the ailment.
U.S. Patent No. 6,884,573
Fixed dried red blood cells and method of use
Inventor(s): Thomas Fischer, Marjorie Read, Arthur Bode, Timothy Nichols
Issued: April 26, 2005
Abstract: Fixed-dried red blood cells (RBCs), and processes for preparing the same are disclosed. The red blood cells, upon reconstitution with distilled water or appropriate buffer: bind oxygen with native affinities, have partial deformability, present minimal thrombogenicity to platelets, and have oblated blood group antigens. The RBCs are preferably fixed by means of cross-linkers with aldehyde functions such as paraformaldehyde or glutaraldehyde either alone or in combination. Native oxygen kinetics are achieved by preparing the red blood cells with 1,6-diphosphofructose. Blood group antigens and chemical functions that render the lyophilized RBCs thrombogenic are occluded by chemically attaching polyoxyethylene glycol polymers to the surface membrane of the red blood cells. The cross-linked red blood cells are preferably died by lyophilization.
